Expression of the Human Concentrative Nucleotide Transporter (hCNT1) Gene Correlates with Clinical Response in Patients Affected by Waldenstrom’s Macroglobulinemia (WM), Undergoing a Combination Treatment with Cladribine (2-CdA) and Rituximab.
Daniele Laszlò(Kantonsspital St. Gallen), Giovanni Martinelli(University of Bologna), Liliana Calabrese(European Institute of Oncology), Alberto Fabbri(Azienda Ospedaliera Universitaria Senese), Ferdinando Frigeri(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Simona Sammassimo(European Institute of Oncology), Luigi Rigacci(Azienda Ospedaliero-Universitaria Careggi), Atto Billio(Ospedale di Bolzano), Graziella Pinotti(Medica (Italy)), Luca Saronni(European Institute of Oncology), Cristina Rabascio(European Institute of Oncology), Giovanna Andreola(European Institute of Oncology)
Cited by 4
Related Papers
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
|Blood|2015|1.2k
Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer
|New England Journal of Medicine|2014|751
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer
|New England Journal of Medicine|2018|684